Shandong Luoxin Pharmacy, a leading pharmaceutical manufacturer in China, has announced that it will become China's first producer of cefazedone sodium and cefazedone sodium for injection.
As the only declarer and developer of cefazedone sodium and cefazedone sodium for injection as a new medicine in the country, the company will receive approval for the first batch of production to become the first company to produce this kind of medicine in China.
Cefazedone sodium and cefazedone sodium for injection, the new Type 3 chemicals the company focuses on, have antibacterial activity and high effect on enterococcus with long half-life and plasma concentration. Therefore, such chemicals are widely used in antibiotics overseas with large market share. Due to the common use of broad-spectrum antibiotics in China and the increasing level of drug resistance, the State Food and Drug Administration has given a notice of promotion on reasonable use of antibiotics to call for doctors' cooperation and encourage the use of narrow-spectrum antibiotics in a bid to minimize negative effects of drugs and drug resistance. Recently, large medical institutions across the country have focused on the application of cephalosporins. It is expected that the Luoxin Pharma's new products, with an extensive sales network, will rapidly gain a large market share, creating benefits and facilitate the Company's large-scale development.
Luoxin Pharma has received approval for the production of five new products this year. The launch of these products has become the Company's growth driver. The Company has also received clinical trial approval for five Type 3 chemicals at the national level, and is actively proceeding with clinical trials of such products for official launches as part of the Company's efforts to follow the 12th Five-year Plan. As China is undergoing urbanization and rapid economic growth, Chinese people's awareness of health has been increased. The rising level of pharmaceutical consumption helps with the rapid development of pharmaceutical companies with high potential. Under such conditions, Luoxin Pharma is stepping up its investment in scientific research as well as innovations to provide more and better high technology pharmaceutical products for the treatment and recovery of patients at large, which has laid a solid foundation for an unrivalled position of the products and rapid, healthy growth of the Company.
Mr. Liu Baoqi, Chairman of Luoxin Pharma, said, "We are glad to be China's first producer of cefazedone sodium and cefazedone sodium for injection. The launch will help to alleviate both the illness and financial burden of patients and encourage our researchers to continue their working on the Type 1 medicine with independent intellectual property rights. We will strive to develop quality pharmaceutical products and make greater contribution to the industry."